Objectives Afatinib, an oral irreversible ErbB family blocker, has demonstrated efficacy in
patients with epidermal growth factor receptor (EGFR) mutation-positive advanced lung …

Introduction Afatinib, an oral irreversible ErbB Family Blocker, has demonstrated efficacy
and safety in epidermal growth factor receptor (EGFR) mutation-positive advanced lung …

Summary Background Afatinib, an irreversible ErbB-family blocker, has shown preclinical
activity when tested in EGFR mutant models with mutations that confer resistance to EGFR …

Background Afatinib is an irreversible ErbB-family blocker with preclinical activity in non-
small-cell lung cancer (NSCLC) with EGFR mutations. We aimed to assess the efficacy of …

LBA7500 Background: Afatinib (A) is a selective, orally bioavailable, irreversible ErbB family
blocker of EGFR (ErbB1), HER2 (ErbB2), and ErbB4. This global study investigated the …

Afatinib is an oral, irreversible, tyrosine kinase inhibitor (TKI) of EGFR, HER2 and HER4.
According to phase I studies, the recommended dose of afatinib was 50 mg daily. Rash …

Purpose New molecular targeted agents are needed for patients with non–small-cell lung
cancer (NSCLC) who progress while receiving erlotinib, gefitinib, or both. Afatinib, an oral …

Abstract Afatinib (Giotrif®, Gilotrif®) is an orally administered, irreversible inhibitor of the
ErbB family of tyrosine kinases. In the first-line treatment of patients with advanced lung …

Abstract Background. Afatinib, an irreversible ErbB family blocker, is approved for treatment
of patients with previously untreated non-small cell lung cancer (NSCLC) harboring …

Abstract Afatinib (Gilotrif™, Giotrif®) is an orally administered, irreversible inhibitor of the
ErbB family of tyrosine kinases. Afatinib downregulates ErbB signalling by covalently …